Cargando…

Burden of Parkinson Disease in China, 1990–2019: Findings from the 2019 Global Burden of Disease Study

INTRODUCTION: China has the most people with Parkinson disease (PD) in the world and is estimated to have over half of the worldwide PD population. The objective of this study was to analyze the corresponding burden of PD in China for the past decades. METHOD: Data on disease burden related to PD in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Zhilin, Zhu, Zeyu, Zhou, Chen, Cao, Lanxiao, Zhao, Guohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064393/
https://www.ncbi.nlm.nih.gov/pubmed/36288688
http://dx.doi.org/10.1159/000527372
_version_ 1785017890923085824
author Zheng, Zhilin
Zhu, Zeyu
Zhou, Chen
Cao, Lanxiao
Zhao, Guohua
author_facet Zheng, Zhilin
Zhu, Zeyu
Zhou, Chen
Cao, Lanxiao
Zhao, Guohua
author_sort Zheng, Zhilin
collection PubMed
description INTRODUCTION: China has the most people with Parkinson disease (PD) in the world and is estimated to have over half of the worldwide PD population. The objective of this study was to analyze the corresponding burden of PD in China for the past decades. METHOD: Data on disease burden related to PD in China were retrieved from the Global Burden of Disease (GBD) 2019 study. The estimated annual percentage changes (EAPCs) were calculated to assess temporal trends, and the ratio of years lived with disability (YLDs) to disability-adjusted life years (DALYs) was used as an index to evaluate the healthcare system. RESULT: Nationally, the burden of PD increased from 1990 to 2019. Although the age-standardized incidence rate (ASIR) increased, the age-standardized death rate (ASDR) and age-standardized DALY rate both decreased. Age-standardized rates of PD in males remained higher than those in females, but trends in ASDR and the age-standardized DALY rate for females showed a pronounced decrease. The most remarkable increase in the ASIR was in individuals aged 45–49 years, with an EAPC of 1.74 (95% confidence interval, 1.26–2.21). The YLDs:DALYs ratio continuously increased compared with global figures and even with countries with high sociodemographic index (SDI). CONCLUSION: Although ASDR and age-standardized DALY rates for PD have been declining, the burden of PD still needs attention as the total numbers have increased over the period. Generally, the greater burden of PD was in males. A sound health system with services tailored to PD continues to be required in the future.
format Online
Article
Text
id pubmed-10064393
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-100643932023-04-01 Burden of Parkinson Disease in China, 1990–2019: Findings from the 2019 Global Burden of Disease Study Zheng, Zhilin Zhu, Zeyu Zhou, Chen Cao, Lanxiao Zhao, Guohua Neuroepidemiology Original Paper INTRODUCTION: China has the most people with Parkinson disease (PD) in the world and is estimated to have over half of the worldwide PD population. The objective of this study was to analyze the corresponding burden of PD in China for the past decades. METHOD: Data on disease burden related to PD in China were retrieved from the Global Burden of Disease (GBD) 2019 study. The estimated annual percentage changes (EAPCs) were calculated to assess temporal trends, and the ratio of years lived with disability (YLDs) to disability-adjusted life years (DALYs) was used as an index to evaluate the healthcare system. RESULT: Nationally, the burden of PD increased from 1990 to 2019. Although the age-standardized incidence rate (ASIR) increased, the age-standardized death rate (ASDR) and age-standardized DALY rate both decreased. Age-standardized rates of PD in males remained higher than those in females, but trends in ASDR and the age-standardized DALY rate for females showed a pronounced decrease. The most remarkable increase in the ASIR was in individuals aged 45–49 years, with an EAPC of 1.74 (95% confidence interval, 1.26–2.21). The YLDs:DALYs ratio continuously increased compared with global figures and even with countries with high sociodemographic index (SDI). CONCLUSION: Although ASDR and age-standardized DALY rates for PD have been declining, the burden of PD still needs attention as the total numbers have increased over the period. Generally, the greater burden of PD was in males. A sound health system with services tailored to PD continues to be required in the future. S. Karger AG 2023-03 2022-10-26 /pmc/articles/PMC10064393/ /pubmed/36288688 http://dx.doi.org/10.1159/000527372 Text en Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
spellingShingle Original Paper
Zheng, Zhilin
Zhu, Zeyu
Zhou, Chen
Cao, Lanxiao
Zhao, Guohua
Burden of Parkinson Disease in China, 1990–2019: Findings from the 2019 Global Burden of Disease Study
title Burden of Parkinson Disease in China, 1990–2019: Findings from the 2019 Global Burden of Disease Study
title_full Burden of Parkinson Disease in China, 1990–2019: Findings from the 2019 Global Burden of Disease Study
title_fullStr Burden of Parkinson Disease in China, 1990–2019: Findings from the 2019 Global Burden of Disease Study
title_full_unstemmed Burden of Parkinson Disease in China, 1990–2019: Findings from the 2019 Global Burden of Disease Study
title_short Burden of Parkinson Disease in China, 1990–2019: Findings from the 2019 Global Burden of Disease Study
title_sort burden of parkinson disease in china, 1990–2019: findings from the 2019 global burden of disease study
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064393/
https://www.ncbi.nlm.nih.gov/pubmed/36288688
http://dx.doi.org/10.1159/000527372
work_keys_str_mv AT zhengzhilin burdenofparkinsondiseaseinchina19902019findingsfromthe2019globalburdenofdiseasestudy
AT zhuzeyu burdenofparkinsondiseaseinchina19902019findingsfromthe2019globalburdenofdiseasestudy
AT zhouchen burdenofparkinsondiseaseinchina19902019findingsfromthe2019globalburdenofdiseasestudy
AT caolanxiao burdenofparkinsondiseaseinchina19902019findingsfromthe2019globalburdenofdiseasestudy
AT zhaoguohua burdenofparkinsondiseaseinchina19902019findingsfromthe2019globalburdenofdiseasestudy